GW Pharmaceuticals plc (NASDAQ: GWPH) is slated to report fourth quarter 2019 earnings results on Tuesday, February 25, after the market closes. Analysts have projected a loss of $0.75 per share on revenues of $105 million.
The company is expected to benefit from strength in sales and growth in prescriptions for Epidiolex. Last quarter, US sales for Epidiolex totaled $86.1 million and the company stated that over 15,000 patients received Epidiolex prescriptions since launch.
GW Pharma continues to work on rolling out Epidiolex in major markets outside the US and it is worth watching how these efforts have paid off. The company is also looking to use Epidiolex in new indications such as Tuberous Sclerosis Complex and is working to gain approval for the same.
The company’s other product Sativex, which is indicated for the treatment of multiple sclerosis, also has significant market opportunity in other indications as well and there are several clinical programs planned for this year.
Also read: GW Pharmaceuticals Q3 2019 Earnings Call Transcript
Last month, GW Pharma released preliminary fourth quarter and full year product sales. The company expects total net product sales to be approx. $108 million for the fourth quarter and approx. $309 million for the full year. Total net product sales of Epidiolex are expected to be around $104 million for the fourth quarter and about $296 million for the full year.
In the third quarter of 2019, the company beat revenue estimates and reported a narrower-than-expected loss. Revenue totaled $91 million, which was above estimates of $85.3 million. Net loss was $13.8 million, or $0.04 per share. Analysts had projected a loss of $0.85 per share.
Shares of GW Pharma have gained 23% in the past three months. The stock has a strong Buy rating and an average price target of $204.43, which represents an upside of 62% from the current level.
Most Popular
PG Earnings: Procter & Gamble Q3 profit climbs, beats estimates
Consumer goods behemoth The Procter & Gamble Company (NYSE: PG) announced financial results for the third quarter of 2024, reporting a double-digit growth in net profit. Sales rose modestly. Core
AXP Earnings: All you need to know about American Express’ Q1 2024 earnings results
American Express Company (NYSE: AXP) reported its first quarter 2024 earnings results today. Consolidated total revenues, net of interest expense, increased 11% year-over-year to $15.8 billion, driven mainly by higher
Netflix (NFLX) Q1 2024 profit tops expectations; adds 9.3Mln subscribers
Streaming giant Netflix, Inc. (NASDAQ: NFLX) Thursday reported a sharp increase in net profit for the first quarter of 2024. Revenues were up 15% year-over-year. Both numbers exceeded Wall Street's
